Aluminum operant chambers measuring 26 Â 26 Â 26 cm (Med Associates Inc., St. Albans, Vermont, USA) were used. The curved rear wall of each chamber contained nine 2.5 cm 2 holes, 2.2 cm deep and 2.3 cm above floor level. Each hole had an infrared photocell beam for detection of nose-poke responses and a 2.8 W bulb at its rear. The side holes were sealed so that only the three or five centrally positioned holes were accessible. A food magazine was located on the opposite wall of the chamber, and a house light was located at the top of this wall. The apparatus was controlled by a computer program written in the MED-PC language (Med Associates Inc.).
The effects of serotonin and/or noradrenaline reuptake inhibitors on impulsive-like action assessed by the three-choice serial reaction time task: a simple and valid model of impulsive action using rats Iku Tsutsui-Kimura, Yu Ohmura, Takeshi Izumi, Taku Yamaguchi, Takayuki Yoshida and Mitsuhiro Yoshioka Impulsivity is a pathological symptom in several psychiatric disorders, underscoring the need for animal models of impulsive action to develop a brief screening method for novel therapeutic agents of impulsive action. The aims of this study were (i) to evaluate whether the three-choice serial reaction time task (3-CSRTT), a simple version of the five-choice serial reaction time task (5-CSRTT), is appropriate for brief assessment of impulsive-like action and (ii) to examine the effects of fluvoxamine, a selective serotonin reuptake inhibitor, and milnacipran, a serotonin/ noradrenaline reuptake inhibitor, on impulsive-like action using the 3-CSRTT. After training in the 3-CSRTT, rats were administered nicotine (0, 0.1, 0.2, and 0.4 mg/kg, salt, subcutaneously), atomoxetine [0, 0.01, 0.1, and, 1.0 mg/kg, intraperitoneally (i.p.)], fluvoxamine (0, 2, 4, and 8 mg/kg, i.p.), or milnacipran (0, 3, and 10 mg/kg, i.p.). The training time for the 3-CSRTT was significantly shorter than that for the 5-CSRTT. Nicotine increased, whereas atomoxetine decreased the number of premature responses, an index of impulsive-like action, which is consistent with earlier studies. Milnacipran, but not fluvoxamine, dose-dependently decreased premature responses. These results indicate that the 3-CSRTT could provide an appropriate and simpler rodent model of impulsive-like action and that milnacipran could have some beneficial effects on impulsivity-related disorders. Behavioural Pharmacology 20:474-483 c 2009 Wolters Kluwer Health | Lippincott Williams & Wilkins.
Introduction
Impulsive actions are often viewed as everyday normal behavior; however, excessive levels of impulsivity are associated with several psychiatric disorders, such as attention-deficit/hyperactivity disorder (AD/HD; Solanto, 2002) , schizophrenia (Potvin et al., 2003; Enticott et al., 2008) , and borderline personality disorder (Paris, 2005) . Moreover, it could be a risk factor for drug addiction, criminal involvement, and suicide (Babinski et al., 1999; Corruble et al., 2003; Ohmura et al., 2005; McGirr et al., 2008) . In particular, suicide in depressed patients is a major worldwide public health problem (Kessler et al., 1999; Coryell and Young, 2005) . Several studies have shown the relationship between impulsivity and suicide (Baca-Garcia et al., 2005; Raust et al., 2006) . Particularly, a recent report found the relationship between impulsive action and suicide attempts in bipolar disorder patients (Swann et al., 2005) . Therefore, we focused on whether some antidepressants can suppress impulsive-like action.
Further development of preclinical models of impulsive action is required to explore novel agents for treating such impulsivity-related disorders. Various preclinical models of impulsivity have contributed to the understanding of the neural correlates of impulsivity and screening for novel therapeutic agents. In this study, we focused on the five-choice serial reaction time task (5-CSRTT), which is one of the most common animal models of impulsive action and is based on the human continuous performance test (Wilkinson, 1963; Robbins, 2002) . This task is performed in an operant chamber containing a horizontal array of five holes. A light in the aperture of one of the five holes is briefly and randomly flashed. Animals are required to make a nose-poke response into the flashed hole to get a food pellet. Responses that occur before the presentation of the stimulus light are described as premature responses and resulted in 5 s time-out period. They are regarded as a form of impulsive-like action, and hence a failure in impulse control (Robbins, 2002) . Thus, premature responses reflect one of the simple forms of impulsivelike action in rodents, and therefore the 5-CSRTT is suitable not only for screening novel treatments but also for revealing the neural basis of impulsive action.
Although this task is useful, it takes a long time to train the animals involved (Puumala et al., 1997) . We had speculated that the number of holes is a critical factor that determines the time required for the completion of training because the higher the number of holes, the more spatial attention is required. Therefore, we established a three-choice serial reaction time task (3-CSRTT). We also evaluated the pharmacological validity of the 3-CSRTT as a brief assessment method for impulsive-like action using nicotine, which is well characterized to provoke impulsive-like action in the 5-CSRTT (Blondel et al., 2000; De Bruin et al., 2006; Van Gaalen et al., 2006) , and atomoxetine, which is well characterized to suppress impulsive-like action in the 5-CSRTT (Blondeau and Dellu-Hagedorn, 2007; Robinson et al., 2008a) .
The evidence that serotonin is profoundly involved in impulse control has been accumulating for a long time (Van Praag and Korf, 1974; Robinson et al., 2008b) . In this study, we examined the effects of fluvoxamine, a selective serotonin reuptake inhibitor, on impulsive-like action as assessed by the 3-CSRTT. This drug is used as an effective treatment for depression (Vaswani et al., 2003) . Although some studies have shown that fluvoxamine suppresses impulsive-like choice in the delay-discounting task in rodents (Bizot et al., 1999; Loiseau et al., 2005) , whether this effect could be extended to impulsive-like action is unknown. This issue should be addressed because the concept of impulsivity consists of several subordinate concepts (Evenden, 1999a; Mitchell, 1999) , and the effects of drugs on impulsive behavior often depend on the type of task used (Talpos et al., 2006 ).
The noradrenergic system is also associated with impulsive-like action. Some studies have shown that some selective noradrenaline reuptake inhibitors suppressed impulsive-like choice and impulsive-like action. For example, maprotiline suppressed impulsive-like choice (Bizot et al., 1988) and atomoxetine suppressed both impulsive-like choice and action (Blondeau and Dellu-Hagedorn, 2007; Robinson et al., 2008a) . Especially, atomoxetine recently came into use for pharmacotherapy of AD/HD. In this study, we examined the effects of milnacipran, a serotonin/noradrenaline reuptake inhibitor, on impulsive-like action. Given that the beneficial effect of milnacipran against depression has been established (Ansseau et al., 1989) and that this drug increases both serotonin and noradrenaline in the synaptic cleft (Stahl et al., 2005; Tachibana et al., 2006) , it may greatly improve impulse control.
The aims of this study were (i) to evaluate the validity of the 3-CSRTT as a brief assessment method for impulsive-like action by comparing the training time for the 3-CSRTT with that for the 5-CSRTT and by examining the effects of nicotine and atomoxetine, which have been well characterized in the 5-CSRTT using the 3-CSRTT, and (ii) to examine the effects of fluvoxamine and milnacipran on impulsive-like action using the 3-CSRTT.
Methods

Subjects
Fifty-nine male Wistar/ST rats were supplied by Nippon SLC Co. Ltd (Hamamatsu, Japan). They were housed in groups of four under an alternating light-dark cycle (light from 19.00 to 07.00 h) at approximately 211C and relative humidity 40-50%. Twenty-six of 59 rats were used to assess the time required for the completion of training in the 3-CSRTT (n = 14) and the 5-CSRTT (n = 12) (Experiment 1). After the experiment, the rats were moved to other studies. The remaining 33 rats received 3-CSRTT training and were allocated to four experiments: eight rats were used for testing nicotine administration (Experiment 2), eight rats were used for testing atomoxetine administration (Experiment 3), eight rats were used for testing fluvoxamine administration (Experiment 4), and nine rats were used for testing milnacipran administration (Experiment 5).
When the rats were 9 weeks old (270-290 g), we started to restrict their food intake so as to maintain their body weights at 85% of those under free-feeding conditions. The daily food of rats in the home cage was purchased from CLEA JAPAN Inc. (CE-2; Tokyo, Japan), and were given after the daily session. Their food intakes in the home cage were 10-15 g in the training period and 10-12 g (plus palatable food pellets 2-3 g in the operant box, see also 3-CSRTT test procedure) in the experimental period. Water was freely available. The treatment of animals complied with the Guidelines for the Care and Use of Laboratory Animals of the Animal Research Committee of Hokkaido University. the number of holes. We used the same training procedure as Ohmura et al. (2009) . In the beginning of the training phase, all hole lights were illuminated for 30 s. In the second phase, one hole light was illuminated randomly for 30 s. In the following phases, the stimulus duration was decreased in a stepwise manner as the training progressed (stimulus duration 15, 10, 5, 3, 2, 1.5, and 1 s). When a rat attained the criteria of greater than 80% accuracy (percentage of correct responses, see 3-CSRTT test procedure and Data analysis) and less than 20% omissions (percentage of omission errors, see Data analysis), it was moved onto the next training phase. The completion of the training was to reach the target phase (stimulus duration 1 s) and to show stable performance for at least three consecutive sessions. Training was conducted for one session per day and six sessions per week.
3-CSRTT test procedure
The task sequence used in the 3-CSRTT was the same as our previous study using the 5-CSRTT (Ohmura et al., 2009 ) except for the number of holes. Briefly, when the task started, the houselight was illuminated. After a fixed intertrial interval (ITI: 5 s), one of three hole lights was illuminated randomly and briefly (stimulus duration: 1 s). Nose poking during the ITI was recorded as a premature response and resulted in turning off all lights (time-out: 5 s), and followed by restarting of the same trial. This parameter was regarded as an index of impulsive-like action. Nose poking into the lit hole while it was illuminated or within a 5 s limited hold was recorded as a correct response and was rewarded by the delivery of a palatable food pellet (45 mg each, dustless precision pellets; Bio-serv, Frenchtown, New Jersey, USA). As an index of attentional function, accuracy (the percentage of correct responses, see Data analysis) was calculated. Nose poking into another hole was recorded as an incorrect response and resulted in a 5 s time-out. The correct response latency, an index of motor function, and the reward latency, an index of motivation and/or appetite, were also measured. The reward latency was the time between a correct response and nose poking into the food magazine. When a rat failed to nose poke within the limited hold, it was recorded as an omission and resulted in a 5 s time-out. This parameter was also regarded as an index of motivation and/or appetite. After a food pellet had been delivered to and collected by a rat, the houselight was turned off for 2 s to allow the rat to eat the pellet before the next trial was automatically started. The start of the next ITI was signaled by turning on the houselight. Additional nose poking into any of the three holes before food collection was recorded as a perseverative response and resulted in a 5 s time-out. This parameter was regarded as an index of compulsive behavior. For further analysis, responses to holes during time-out period were also counted, though these responses had no consequence. As the trial was initiated automatically, we did not set a time restriction for this task. Each session consisted of 100 trials.
The current version of the task sequence (Ohmura et al., 2009 ) differed from the original version (Carli et al., 1983) in some aspects. Premature responses were followed by the restart of the same trial, but not by the start of the next trial. Each trial was initiated automatically, not by a panel push. In this way, the rat was required to use more attentional resources (Semenova et al., 2007) because it could not proceed with the task at its own pace. Furthermore, the stimulus duration was 1 s instead of 0.5 s, because we used Wistar rats, which show poor attention and high impulsive-like action compared with Lister hooded rats (Broersen and Uylings, 1999; Ohmura et al., 2009 ).
Baseline performance assessment and drug treatment schedule
Once the performance had been stabilized for at least three consecutive sessions, the experiments were started. We used the data from the last 3 days of training to provide a preexperimental baseline index of performance. Drug treatments were carried out with a Latin square design. The experimental baseline was assessed on Tuesdays and Fridays, and drugs were administered on Wednesdays and Saturdays. The training time (sessions) to complete the training in the 3-CSRTT (n = 14) and that in the 5-CSRTT (n = 12) were compared to examine the validity of the 3-CSRTT as a brief assessment method of impulsive action. When the rats achieved stable performance, it was regarded as the completion of the training. We set the criteria for determining stable performance as follows: the change in premature responses stayed within ± 25%, the accuracy stayed within ± 5%, and percentage response omissions were less than 20% for three consecutive sessions. We also compared behavioral parameters in the two tasks, such as premature responses, accuracy, percentage response omissions, perseverative responses, correct response latency, reward latency, correct responses, and responses during time-out period. The mean value of three consecutive sessions in the stable performance phase was used for each comparison. Eight rats received an administration of atomoxetine [0, 0.01, 0.1, and 1.0 mg/kg, intraperitoneally (i.p.)] 30 min before the testing. The doses of atomoxetine were chosen on the basis of earlier studies using the 5-CSRTT (Blondeau and Dellu-Hagedorn, 2007; Robinson et al., 2008a) .
Experiment 4: the effects of fluvoxamine on impulsivelike action measured by the 3-CSRTT Eight rats received an administration of fluvoxamine (0, 2, 4, and 8 mg/kg, i.p.) 30 min before the testing. The doses of fluvoxamine were chosen on the basis of earlier studies that assessed impulsive-like choice in rats using the delay-discounting task (Bizot et al., 1999; Loiseau et al., 2005) .
Experiment 5: the effects of milnacipran on impulsivelike action measured by the 3-CSRTT Nine rats received an administration of milnacipran (0, 3, and 10 mg/kg, i.p.) 60 min before the testing. The doses of milnacipran were chosen on the basis of an earlier study (Rénéric and Lucki, 1998) .
Drugs
( -)-Nicotine hydrogen tartrate salt and (R)-tomoxetine hydrochloride (atomoxetine hydrochloride) were purchased from Sigma-Aldrich (St. Louis, Missouri, USA). Fluvoxamine maleate was purchased from Tocris (Hung road, Bristol, UK). Milnacipran hydrochloride was generously donated by Asahi-Kasei Co. Ltd (Tokyo, Japan). Nicotine, atomoxetine, and fluvoxamine were dissolved in 0.01 mol/l PBS to adjust the pH of resulting solution to 6.5. These three compounds were administered at a volume of 1 ml/kg. Milnacipran was dissolved in sterile saline (pH 6.5) and administered at a volume of 3 ml/kg, based on our preliminary examination and earlier studies (Rénéric and Lucki, 1998; Matsumoto et al., 2005) .
Data analysis
Training time and the following eight behavioral measures were analyzed:
(1) Premature responses (no. per session). It should be noted that the percentage of omissions is equal to the number of omissions in this study because a premature response restarted the same trial and we did not set a time limit.
Before the statistical analyses, we conducted Shapiro-Wilk tests for all eight behavioral parameters and training periods of both tasks. If we could not assume the normal distribution, the following data transformation were carried out to normalize data: percentage response omissions were arcsine transformed; premature responses and perseverative responses were subjected to square root transformations; latencies were subjected to customary logarithm transformation. Following that, Mauchly's sphericity test was conducted for analysis of variance (ANOVA) and Levene test for t-test. Sphericity assumption and equality of variance were not denied for any measure after transformations. As training time could not be normalized by transformations, Mann-Whitney U test was used for these data. The figures show raw data rather than transformed data.
For nicotine, atomoxetine, fluvoxamine, milnacipran dose-response experiments, each measure was analyzed separately by two-factor ANOVA for repeated measures with rank of dose injection as between-subject factor and dose as within-subject factor. Multiple comparisons with Bonferroni's correction were also conducted.
Baseline behavioral data were subjected to repeatedmeasures ANOVA.
The a level was set at 0.05 for all statistical procedures. All statistical procedures were conducted using SPSS (version 15.0 J; SPSS Inc., Chicago, Illinois, USA).
Results
Experiment 1: a comparison of the time required for the completion of the training and behavioral parameters in the 3-CSRTT with those in the 5-CSRTT
The mean number of sessions necessary to complete the training in the 3-CSRTT was significantly lower than that in the 5-CSRTT (Table 1; 29.93 ± 3.39 vs. 52.58 ± 2.08, respectively, z = -3.65, P < 0.05). This analysis indicated that the use of the 3-CSRTT successfully saved about 4 weeks (six sessions per week) compared with the 5-CSRTT.
Analysis of the behavioral parameters measured by these two tasks (Table 1) showed that accuracy and correct responses in the 3-CSRTT were significantly higher than those in the 5-CSRTT [t(24) = -9.31, P < 0.05; t(1,24) = -6.86, P < 0.05, respectively]. Moreover, correct response latency in the 3-CSRTT was faster than that in the 5-CSRTT [t(24) = 2.85, P < 0.05]. Other parameters did not differ significantly between the two tasks. . There were no significant main effects of rank of dose injection, or dose Â rank interactions for these three parameters. A multiple comparison with Bonferroni's correction showed that the 0.2 mg/kg dose of nicotine significantly increased the number of premature responses compared with vehicle or the 0.1 mg/kg dose (P < 0.05).
The effects of nicotine on perseverative responses, latencies, correct responses, and responses during timeout period were also analyzed ( Table 2) There was no significant dose Â rank interaction for any of these five parameters. However, the effects of nicotine on correct response latency and responses during time-out period failed to reach significance in multiple comparisons with Bonferroni's correction, though main effects of dose were significant.
Experiment 3: the effects of atomoxetine on impulsivelike action measured by the 3-CSRTT Figure 1d -f shows the effects of atomoxetine on premature responses, percentage correct responses (accuracy), and percentage response omissions. The ANOVA showed a significant dose effect on premature responses [F(3,21) = 12.81, P < 0.05], but not on accuracy [F(3,21) = 0.58, NS] or percentage response omissions [F(3,21) = 3.17, NS]. There were no significant main effects of rank of dose, or dose Â rank interactions for any of these three parameters. A multiple comparison with Bonferroni's correction showed that 1.0 mg/kg dose of atomoxetine significantly reduced the number of premature responses compared with vehicle (P < 0.05).
The effects of atomoxetine on perseverative responses, latencies, correct responses, and responses during the time-out period were also analyzed ( Table 2) The effects of fluvoxamine on perseverative responses, latencies, correct responses, and responses during timeout period were also analyzed ( Table 2) . Fluvoxamine produced a significant main effect of dose on correct responses [F(3,21) = 9.86, P < 0.05], but no effect on perseverative responses [F(3,21) = 0.59, NS], correct response latency [F(3,21) = 1.45, NS], reward latency [F(3,21) = 0.74, NS], and responses during the time-out period [F(3,21) = 2.01, NS]. Main effects of rank of dose injection and dose Ârank interactions were not significant for these five parameters. A multiple comparison with Bonferroni's correction showed that 8.0 mg/kg of fluvoxamine significantly reduced the number of correct responses compared with the vehicle (P < 0.05).
Experiment 5: the effects of milnacipran on impulsivelike action measured by the 3-CSRTT Figure 1j -l shows the effects of milnacipran on premature responses, percentage correct responses (accuracy), and percentage response omissions. The ANOVA revealed a significant dose effect on premature responses Baseline performance assessment Figure 2 shows the preexperimental and experimental baseline and control vehicle-administration performance levels for premature responses, accuracy, and percentage response omissions for the four groups of rats (nicotine, atomoxetine, fluvoxamine, and milnacipran), over seven (milnacipran) or eight (nicotine, atomoxetine, and fluvoxamine) sessions. Repeated-measures ANOVA showed no significant effects of day, in any of the four groups, on premature responses [nicotine: F(7,49) = 1.88, NS; atomoxetine: F(7,49) = 0.89, NS; fluvoxamine: F(7,49) = 1.932, NS; and milnacipran; F(6,48) = 2.12, NS], accuracy [nicotine: F(7,49) = 2.17, NS; atomoxetine: F(7,49) = 0.52, NS; fluvoxamine: F(7,49) = 1.93, NS; milnacipran: F(6,48) = 1.08, NS], or percentage response 
Discussion
This study showed that the training time required reaching the criteria (see Methods) was significantly shorter for the 3-CSRTT than that for the 5-CSRTT. Accuracy and the number of correct responses in the 3-CSRTT were higher than those in the 5-CSRTT. Correct response latency in the 3-CSRTT was faster than that in the 5-CSRTT. Other parameters, including premature responses, did not differ between the two tasks. Nicotine administration significantly increased the number of premature responses and decreased correct response latency in the 3-CSRTT, which is consistent with earlier studies using the 5-CSRTT (Blondel et al., 2000; De Bruin et al., 2006; Van Gaalen et al., 2006) . Atomoxetine selectively and dose-dependently suppressed impulsive-like action in the 3-CSRTT, which is also consistent with earlier reports using the 5-CSRTT (Blondeau and Dellu-Hagedorn, 2007; Robinson et al., 2008a) . These results indicate that the 3-CSRTT is appropriate as a brief assessment of impulsive-like action in rats. Furthermore, we found that the administration of 10 mg/kg milnacipran significantly suppressed impulsivelike action without affecting any other parameters in the 3-CSRTT, whereas all doses of fluvoxamine failed to alter impulsive-like action in this study.
Lister hooded rats are often used in the 5-CSRTT. If we had used them in the 3-CSRTT, the duration of training might have been shortened further because they generally show higher performance in the 5-CSRTT. Nevertheless, we used Wistar strain rats because they are easily handled and show relatively high impulsive-like action (Broersen and Uylings, 1999; Semenova et al., 2007) . In addition, if the number of holes had been decreased, the duration of training may have been shortened further because an earlier report using two-lever choice task showed that rats moved onto experimental periods only with 24 sessions of training (Evenden, 1999b) . However, we chose the three-hole task because the chance performance level of the two-hole task is high (50%). Moreover, the number of premature responses dramatically increased (> 100) when we used the one-hole task with Wistar strain rats (unpublished data), as we could not determine whether a rat had nose poked in response to hole light or had just nose poked randomly. Decreasing the number of holes may increase random nose pokes and data variability (Robbins, 2002) even in the three-hole task. However, in the 3-CSRTT, chance performance level is still 33.33% and the average level of accuracy in this study was 82.23% (Table 1) , indicating that performance level in this study was clearly higher than chance level. Although chance performance level in the 5-CSRTT is low (20%), it should be noted that the performance level was also low (the average of accuracy was 63.2%, Table 1 ). Furthermore, there were no significant differences in the number of responses to holes during the time-out period or the SEM Table 2 Effects of nicotine (n = 8), atomoxetine (n = 8), fluvoxamine (n = 8), and milnacipran (n = 9) on perseverative responses, correct response latency, reward latency, correct responses, and responses during time-out period assessed by the 3-CSRTT of all behavioral parameters between the 5-CSRTT and 3-CSRTT (Table 1) . Thus, there is no objective evidence indicating that using the 3-CSRTT in this study increased random nose pokes and data variability compared with the 5-CSRTT.
The significant increase of premature responses by nicotine administration was only observed with the intermediate of the three tested doses. As the largest dose of nicotine (0.4 mg/kg) also somewhat increased percentage response omissions (but not statistically significantly, Fig. 1c ) and significantly reduced responses to holes during the time-out period ( Table 2) , we suggest that this bell-shaped dose-response curve of premature responses was derived from motor depression. Some earlier studies assessing the motor depressant effect of nicotine on locomotor activity in nicotine-naive rats support this speculation (Clarke and Kumar, 1983; Welzl et al., 1990) . The number of premature responses was increased more by nicotine in this study than in earlier studies reporting the effects of nicotine in the 5-CSRTT (De Bruin et al., 2006; Van Gaalen et al., 2006) . Since Blondel et al. (2000) showed that the effects of nicotine on premature responses were higher in rats showing a higher baseline of premature responses than in rats showing lower baseline of premature responses, this result was possibly derived from higher baseline of premature responses in the nicotine treated group (Fig. 2) .
Accuracy was not altered in this study, though some studies reported that the administration of nicotine enhanced attentional performance in the 5-CSRTT (Mirza and Stolerman, 1998; Hahn et al., 2002; Bizarro et al., 2004) . This discrepancy may be because of differences in the attentional demands of the task between earlier studies and this study. Indeed, Mirza and Stolerman (1998) found a nicotine enhancement effect on attentional performance only when the attentional demands were increased by prolonging the ITI to 20 s, whereas some other studies found an effect of nicotine on attentional performance under standard conditions (Hahn et al., 2002; Bizarro et al., 2004) . Although the 3-CSRTT is appropriate for a brief assessment of impulsive action, its sensitivity for detecting slight changes in attentional function may be somewhat restricted. Further studies will be needed to clarify this point.
Atomoxetine dose-dependently suppressed impulsivelike action in the 3-CSRTT, consistent with earlier reports using the 5-CSRTT (Blondeau and Dellu-Hagedorn, 2007; Robinson et al., 2008a) . This indicates that the 3-CSRTT can appropriately detect a decrease and also an increase of impulsive-like action.
Although some studies have shown that fluvoxamine suppresses impulsive-like choice in the delay-discounting task (Bizot et al., 1999; Loiseau et al., 2005) , fluvoxamine did not affect impulsive-like action in this study. Indeed, it has been suggested that impulsivity consists of several subordinate concepts (Evenden, 1999a; Mitchell, 1999) . A growing body of data from preclinical studies has shown that impulsive behavior can be divided into at least two main categories. One is a behavior that results from difficulties in the ability to inhibit actions, often referred to as 'impulsive action'. The level of impulsive-like action could be assessed by using 5-CSRTT and 3-CSRTT. Another is a behavior that reflects impulsive decisionmaking or choice, often referred to as 'impulsive choice'. The level of impulsive-like choice could be assessed by using a delay-discounting task. Although, there are shared brain areas and receptors responsible for these two behaviors, there are also dissociable brain areas and receptors (Pattij and Vanderschuren, 2008) . Therefore, the effects of drugs on impulsive behavior often depend on the type of task used, possibly because each task assesses different aspects of impulsivity (Talpos et al., 2006) .
In this study, the highest dose of fluvoxamine (8 mg/kg) slightly, but significantly, impaired accuracy. As percentage response omissions were also somewhat increased (but not statistically significantly, Fig. 1c ), these effects may reflect sedation induced by fluvoxamine. In fact, the number of responses during the time-out period was also somewhat decreased (Table 2) . Alternatively, fluvoxamine may impair attentional function, but this effect is not such a critical problem because accuracy was still maintained at a high level (approximately 80%) even at that dose.
The administration of the 10 mg/kg dose of milnacipran, a well-established serotonin/noradrenaline reuptake inhibitor, reduced impulsive-like action in the 3-CSRTT without changing other indices of cognitive function, such as attentional function, motivation/appetite, compulsive behavior, or motor function. These results indicate that milnacipran is a potential therapeutic agent for impulsivity-related disorders. As our preliminary experiment had shown that a higher dose (30 mg/kg) of milnacipran induced apparent motor depression, we did not use a higher dose ( > 10 mg/kg) in this study. Treatments with selective and nonselective noradrenaline reuptake inhibitors, such as atomoxetine and desipramine, have been shown to produce a reduction in impulsive-like action (Van Gaalen et al., 2006; Blondeau and Dellu-Hagedorn, 2007; Robinson et al., 2008a) .
Moreover, fluvoxamine, a selective serotonin reuptake inhibitor, failed to suppress impulsive-like action in this study. Taken together, these results suggest that the ability of milnacipran to suppress impulsive-like action is because of its blockade of the noradrenaline transporter, but not of the serotonin transporter. Indeed, earlier studies have indicated that a-1 and a-2 adrenoceptors are involved in impulsive-like action in the 5-CSRTT (Puumala et al., 1997; Koskinen et al., 2003) . Nevertheless, it is difficult to conclude that the reduction of impulsivelike action observed in this study is accounted for by an increase in noradrenergic neurotransmission because of the blockade of the noradrenaline transporter, because this transporter takes up not only extracellular noradrenaline but also dopamine in some specific brain regions, such as the medial prefrontal cortex and the nucleus accumbens shell (Carboni et al., 1990; Pozzi et al., 1994; Yamamoto and Novotney, 1998) . Indeed, acute administration of milnacipran increases extracellular concentrations of dopamine in the rat medial prefrontal cortex (Kitaichi et al., 2005) . Furthermore, rats with prefrontal dopamine depletions were found to have impaired impulse control (Sokolowski and Salamone, 1994) . Thus, at this time, we cannot determine whether the effects of milnacipran observed in the present study were because of increased noradrenaline or dopamine. To clarify this point, further studies are needed.
As stated above, milnacipran suppressed impulsive-like action without affecting other cognitive functions. Moreover, a case report described an adult AD/HD patient whose inattention and hyperactivity, as assessed by the continuous performance test, were remarkably alleviated by chronic administration of milnacipran (Kako et al., 2007) . Our results and this report suggest that milnacipran is not only an antidepressant, but could also be a beneficial treatment for impulsivity-related disorders, such as AD/HD, schizophrenia, and borderline personality disorder. In addition, milnacipran may lower the risk of suicide in depressed patients, which is a major public health problem.
In conclusion, our present results support the validity of the 3-CSRTT as a brief method for the assessment of impulsive-like action. This preclinical model will contribute to the better understanding of the neural basis of impulsive action and help to explore novel treatments for impulsivity-related disorders. We have also shown that milnacipran, but not fluvoxamine, suppresses impulsive-like action without affecting other cognitive functions, indicating that milnacipran could be a beneficial treatment for impulsivity-related disorders.
